Male
Multidisciplinary Team(s)
Gastrointestinal Oncology
Department/Research Program(s)
Department of Oncology
Molecular Imaging Diagnostics Program
Cancer Type(s)
Ampullary and periampullary cancers
Anal Cancer
Appendix Cancer
Bile Duct Cancer
Cancer of unknown origin
Carcinoid Tumors
Cholangiocarcinoma
colon Cancer
Esophageal Cancer
Gall Bladder Cancer
Gastroesophageal Junction (GEJ)
Gastrointestinal Stromal Tumors (GIST)
Liver Cancer
Neuroendocrine Tumors
Pancreatic Cancer
Pancreatic Neuroendocrine Tumor (pNET)
Peritoneum and psuedomyxoma peritonii
Rectal Cancer
Small Intestine Cancer
Stomach Cancer
Contact Info
Email:
shieldsa@karmanos.org
来自 http://www.karmanos.org/physicians/Anthony-Shields?Disease=238PageIndex=0SortDirection=1
Education
Fellowship
Medical oncology Fellowship: University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington
Medical School
Harvard Medical School
Residency
Internal Medicine, University of Washington School of Medicine, Seattle, Washington
Graduate Training
Massachusetts Institute of Technology (Ph.D)
Professional Memberships/Associations
American Society of Clinical Oncology
American Society of Hematology
Society of Nuclear Medicine
American Association for Cancer Research
American Society for Microbiology
World Molecular Imaging Society
Board Certifications
American Board of Internal Medicine
National Board of Medical Examiners
American Board of Medical oncology and Hematology
Clinical Interests
Medical Oncology, Gastrointestinal Oncology
Research Interests
Gastrointestinal Oncology, Molecular Imaging to assess treatment response, Imaging Agents
Profile
Dr. Shields' career has been dedicated to clinical research and the care of patients with colorectal, pancreatic and other gastrointestinal cancers. His experiences in research and the clinic make him painfully aware of the need to develop new approaches in understanding and overcoming resistance to treatment for patients with GI cancer. At Karmanos Cancer Institute and Wayne University School of Medicine he leads clinical research efforts through his roles as the Associate Center Director for Clinical Sciences, Program Leader in Molecular Imaging and Diagnostics and Professor of oncology and Medicine. Dr. Shields training as a Medical oncologist provides the insight to guide studies in patients with cancer and the foresight to design trials that are appropriate. He has a broad understanding in clinical sciences with experience that spans from protocol design and development to implementation from the local to the national level. He is the sub-chair for colorectal cancer at the Southwest oncology Group (SWOG), and co-chair for a national adjuvant colon cancer study sponsored by the Cancer and Leukemia Group B (CALGB) and SWOG. He serves on the NCI colon Task Force, which is charged with overseeing clinical research studies in colorectal cancer, and has served on the NCI Investigational Drug Steering Committee. In the clinic, his work concentrates on the treatment of patients with gastrointestinal (GI) cancer and he continues to develop and lead new clinical trials for GI tumors. This includes serving as a founding faculty member of the Clinical Trials Methodology Workshop under the sponsorships of the Radiological Society of North America (RSNA) and the National Cancer Institute, which is designed to mentor new faculty. As an Associate Center Director for Clinical Sciences, and member of the Human Investigation Committee Review Board, he helps to oversee a large number of clinical studies within our Institute and comprehends the complexities and challenges of the approaches to successful evaluation of new agents. Dr. Shields clearly has a crucial role in the design of cancer clinical trials. His laboratory research focuses on the development and testing of tracers for use with positron emission tomography (PET) for the assessment of a variety of tumors (e.g. brain, lung, breast, and prostate cancers) and their response to treatment. Dr. Shields led the development of FLT {3'-deoxy-3'-fluorothymidine}; a promising tracer for tumor proliferation, which has received an IND from the FDA and is being tested in centers worldwide. He serves on the Steering Committee of the American College of Radiology (ACRIN) and the National oncology PET Registry (NOPR) and works to incorporate innovative imaging in the multicenter clinical trials. He is Senior Editor for Molecular Imaging and Biology and the Journal of Nuclear Medicine, and a reviewer for a number of journals, including the New England Journal of Medicine, Nature Medicine, and The Journal of Clinical Oncology. He has authored over 100 peer-reviewed articles and more than 20 book chapters, reviews and case reports on cancer research.
Awards
2005, 2009-2013 Voted one of the Best Doctor's in America by Best Doctors Inc.
Selected by Castle Connolly Medical Ltd. as one of the region's Top Doctors
2007Wayne State University Distinguished Faculty Fellowship Award
2005European Association of Nuclear Medicine and Springer-Verlag Award - Best Clinical Paper
2005Peter Valk Distinguished Clinical Scientist Award, Academy of Molecular Imaging
Publications
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 307:1383-93. 2012. PMID: 22474202 Authors: Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM.
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs, 29:694-9, 2011. Epub Jan 27, 2010. PMID: 20107864. Authors: El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL.
Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience. Am J Clin Oncol. 34:135-9. 2011. PMID: 20523206 Authors: Hammad N, Heilbrun LK, Gupta S, Tageja N, Philip PA, Shields AF, Smith D, El-Rayes BF
Impact of dedicated brain PET on intended patient management in participants of the National oncologic PET Registry. Mol Imaging Biol. 13:161-5, 2011. Epub Oct 7, 2010. PMID: 2108023 Authors: Hillner BE, Siegel BA, Shields AF, Fenghai D, Gareen IF, Hanna L, Coleman RE.
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs. 29: 1395-405, 2011. Epub Jul 6, 2010. PMID: 20607586 Authors: Lorusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie T, Puchalski T, Xu J, Liu Q.
